Status:

COMPLETED

TMS in Aphasia Recovery

Lead Sponsor:

University of Pennsylvania

Conditions:

Aphasia

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Stroke often causes substantial problems in speaking or understanding speech. Treatments for these problems are currently very limited. Limited studies to date suggest that repetitive Transcranial Mag...

Eligibility Criteria

Inclusion

  • Aphasic patients will have had single, unilateral left hemisphere ischemic stroke, which spared the supplementary motor area (SMA)
  • With the exception of lacunar infarcts less than ≤ 1.5 cm (as measured by neuroimaging), the stroke causing the patients' impairments must be the only stroke.
  • Aphasic patients will be at least 6 months post-stroke and have mild-severe, non-fluent speech
  • Participants must be able to understand the nature of the study, and give informed consent

Exclusion

  • Patients with more than one stroke
  • Primary hemorrhagic stroke. Note: It is recognized that some ischemic strokes may have a minor amount of hemosiderin in the parenchyma. If this occurs, this is not considered a "hemorrhagic stroke" referred to in this exclusion criterion.
  • Intracranial metallic bodies from prior neurosurgical procedure
  • Signs of increased intracranial pressure as assessed by ophthalmic exam and patient symptoms
  • Implanted pacemaker, medication pump, vagal nerve stimulator, deep brain stimulator, TENS unit or ventriculoperitoneal shunt
  • History of seizure or unexplained loss of consciousness during the year prior to the initiation of the study
  • Pregnancy. If the patient cannot rule out pregnancy then a pregnancy test will be conducted prior to inclusion into the study
  • Family history of epilepsy
  • Acute, unstable medical conditions
  • History of substance abuse within the last 6 months
  • Abnormal neurologic exam other than as signs of the condition studied in the present protocol
  • History of known structural brain abnormality other than as signs of the condition studied in the present protocol
  • History of tinnitus
  • History of bipolar disorder
  • Consumption of medicines known to lower the seizure threshold
  • History of head injury with unconsciousness lasting more than 5 minutes
  • Previous brain surgery
  • Other medical or neurologic conditions, aside from stroke, in which the likelihood of developing a seizure is known to be increased
  • Other medical or neurologic conditions, in which a seizure would be particularly harmful
  • Significant cardiac disease
  • Intracardiac lines of any type
  • Current serious or unstable medical illness, including renal, hepatic, cardiovascular, gastrointestinal, endocrinologic, neurologic, immunologic, or hematological disease, that could require admission to a hospital within 3 months, or that death is anticipated within 3 years, or that requires daily supervision by a health professional
  • Administration of any investigational drug within 5 half-lives of the drug prior to testing

Key Trial Info

Start Date :

June 26 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 30 2011

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT04777214

Start Date

June 26 2007

End Date

August 30 2011

Last Update

November 26 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104